Boiron SA (EPA:BOI)

Market Cap	453.16M +22.2%
Revenue (ttm)	501.11M +2.8%
Net Income	32.64M +188.0%
EPS	1.88 +188.0%
Shares Out	17.36M
PE Ratio	13.88
Forward PE	n/a
Dividend	1.35 (5.19%)
Ex-Dividend Date	Jun 3, 2026

Volume	53
Open	26.10
Previous Close	26.00
Day's Range	25.90 - 26.20
52-Week Range	21.00 - 32.25
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 18, 2026

About Boiron

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices (in vitro diagnostics), dietary supplements, herbal remedies, cosmetics, and CBD-based products. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive l...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 2,634
• Stock Exchange: Euronext Paris
• Ticker Symbol: BOI

Financial Performance

In 2025, Boiron's revenue was 501.11 million, an increase of 2.78% compared to the previous year's 487.56 million. Earnings were 32.64 million, an increase of 187.96%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 21, 2026

Data Sources Report a data error